Anorexia Nervosa, Bariatric Surgery, Weight Change, Body
Conditions
Keywords
adipocytokines, leptin, adiponectin, omentin, apelin, IL-6, Anorexia Nervosa, Bariatric Surgery, fat mass
Brief summary
In this study, when patients diagnosed with AN started treatment and their weight increased by 10%; On the other hand, it was aimed to compare the changes in serum adipokine levels observed in morbidly obese patients before bariatric surgery and when they lost 10% of their post-op weight with both anthropometric measurements, biochemical parameters, and values of healthy volunteers.
Detailed description
The most characteristic feature of obesity is the increase in adipose tissue. On the contrary, in anorexia nervosa, there is a decrease in adipose tissue enough to impair neuroendocrine functions. Adipose tissue is formed by loosely binding lipid-filled cells called adipocytes and is now considered an important part of energy metabolism. Adipokines it secretes play a role in many physiological processes of the body such as nutrition, appetite, energy balance, insulin, and glucose metabolism, lipid metabolism, regulation of blood pressure, vascular remodeling, coagulation, and inflammation. Therefore, changes in the amount of body fat in these two patient groups, which are at the two ends of the spectrum, affect both the biochemical parameters and physiological functions of the patients in different ways. It is expected that both adipokine levels and biochemical parameters will approach the values of healthy subjects with a decrease in adipose tissue of clinically morbidly obese patients and an increase in adipose tissue of patients with AN. However, in some studies comparing the parameters of patients with constitutionally weak patients and patients with AN, results contrary to expectations were obtained. In this study, we compared the extent to which weight changes changed adipokines and correlated with biochemical parameters based on healthy and normal-weight volunteers.
Interventions
PROCEDUREBariatric surgery-RYGB
After the creation of a 15-25-cc gastric pouch from the upper stomach, transection of proximal jejunum 70 cm from Treitz ligament also called alimentary tract and anastomosis of the distal end of jejunum to the gastric pouch, and thereafter, anastomosis of the proximal end of transected jejunum to the distal part of the jejunum at 150 cm below the site of transection (jejunoileal anastomosis).
BEHAVIORALDietary intervention
High-calorie medical nutrition program to ensure weight gain
Sponsors
Istanbul University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* for Anorexia Nervosa group: * Have been diagnosed with anorexia nervosa * BMI \<18 kg/m2 * Good general health * Volunteering to participate in the study * for Morbidly Obese group: * Who was diagnosed with morbid obesity and planned to undergo RYGB operation * BMI\> 40 kg/m2 * Volunteering to participate in the study * for Healthy Volunteers: * Good general health * BMI \>20 and \<30 kg/m2 * Volunteering to participate in the study
Exclusion criteria
* \<13 and\> 60 years old * to had type 2 diabetes, hypertension, liver and kidney failure, cancer, or a chronic disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Omentin levels changes | 3 months on average | Change in baseline Omentin levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples. |
| Plasma Leptin levels changes: | 3 months on average | Change in baseline Leptin levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples. |
| Plasma Apelin levels changes | 3 months on average | Change in baseline Apelin levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples. |
| Plasma IL-6 levels changes | 3 months on average | Change in baseline IL-6 levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples. |
| Plasma Adiponectin levels changes | 3 months on average | Change in baseline Adiponectin levels at when decreasing by 10 percent or increasing by 10 percent from initial weight. Measured by plasma samples. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fat free mass changes | 3 months on average | Change in baseline fat free mass (kg) at when decreasing by 10 percent or increasing by 10 percent from initial weight. |
| Weight change | 3 months on average | Change in baseline weight (kg) at when decreasing by 10 percent or increasing by 10 percent from initial weight. |
| Fat mass change | 3 months on average | Change in baseline fat mass (kg) at when decreasing by 10 percent or increasing by 10 percent from initial weight. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Serum glucose change | 3 months on average | Change in baseline glucose (mg/dl) at when decreasing by 10 percent or increasing by 10 percent from initial weight. |
| Serum CRP change | 3 months on average | Change in baseline CRP at when decreasing by 10 percent or increasing by 10 percent from initial weight. |
| Serum insulin change | 3 months on average | Change in baseline insulin (µU/mL) at when decreasing by 10 percent or increasing by 10 percent from initial weight. |
Outcome results
None listed